More Information

Submitted: July 21, 2022 | Approved: August 01, 2021 | Published: August 02, 2022

How to cite this article: Jordán EV, Puertas AN, Señor BV, Pellejero JC, Monsteirín NF, et al. Role of perioperative plasma D-dimer in intracerebral hemorrhage after brain tumor surgery: A prospective study. J Neurosci Neurol Disord. 2022; 6: 024-031.

DOI: 10.29328/journal.jnnd.1001064

Copyright License: © 2022 Jordán EV, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Keywords: D-dimer; Intracerebral hemorrhag; Tumor; Neurosurgery Coagulation; Biomarker; Bleeding; Intracranial hypertension

Abbreviations: APTT: Activated Partial Thromboplastin Time; CT: Computerized Tomography; Fb: Fibrinogen; FP: Frozen Plasma; G6PDD: Glucose-6-Phosphate Dehydrogenase Deficiency; Hb: Hemoglobin; Ht: Hematocrit; ICH: Intracranial Hemorrhage; IH: Intracranial Hypertension; INR: International Normalized Ratio; P: Platelets; PA: Prothrombin Activity; PCR: Prothrombin Complex; PP: Pooled Platelets; RBC: Red Blood Cells; TXA: Tranexamic Acid

 FullText PDF

Role of perioperative plasma D-dimer in intracerebral hemorrhage after brain tumor surgery: A prospective study

Estela Val Jordán1*, Agustín Nebra Puertas2, Beatriz Virgos Señor2, Juan Casado Pellejero3, Nuria Fernández Monsteirín4, Lluis Serviá Goixart5, Silvia Rodríguez Ruiz5, Nuria Ramón Coll5, Gabriel Jiménez Jiménez5, Manuel Quintana Díaz6, David Fuentes Esteban7, Concepción Revilla López8 and Jesús Caballero López6

1Department of Critical Care, Arnau de Vilanova University Hospital (Lleida, Spain), Military Hospital and Miguel Servet University Hospital. Paseo Isabel La Católica, 1-3. 50009. Zaragoza, Spain
2Department of Critical Care. Miguel Servet University Hospital. Paseo Isabel La Católica, 1-3. 50009. Zaragoza, Spain
3Department of Neurosurgery, Miguel Servet University Hospital, Paseo Isabel La Católica, 1-3,50009, Zaragoza, Spain
4Department of Coagulation, Miguel Servet University Hospital, Paseo Isabel La Católica, 1-3, 50009, Zaragoza, Spain
5Department of Critical Care. Institut de Reserca Biomèdica. Arnau de Vilanova University Hospital, Av. Alcalde Rovira Roure, 80, 25198, Lleida, Spain
6Department of Critical Care, La Paz University Hospital, Paseo de la Castellana, 261, 28046, Madrid, Spain
7Department of Critical Care. Military Hospital. Vía Ibérica 1. 50009. Zaragoza, Spain
8Department of Statistics, Miguel Servet University Hospital, Paseo Isabel La Católica, 1-3, 50009, Zaragoza, Spain

*Address for Correspondence: Estela Val Jordán Department of Critical Care, Miguel Servet University Hospital, Paseo Isabel La Católica, 1-3, 50009, Zaragoza, Spain, Email:

Background: Intracerebral hemorrhage (ICH) is one of the most feared complications after brain tumor surgery. Despite several factors being considered to influence bleeding, an increasing number of clinical studies emphasize that hemostatic disorders, developed during surgical aggression and tumor status, could explain unexpected ICH. The objective of this prospective study was to evaluate the influence of perioperative D-dimer levels on ICH after brain tumor surgery.

Methods: This prospective, observational, 18-month study, at a single third-level hospital, included all consecutive adults operated on brain tumors and postoperative stay in an intensive care unit. Three blood samples evaluated D-dimer levels (A-baseline, B-postoperative and C-24 hours after surgery). The normal range considered was 0-500 ng/ml. ICH, as a primary outcome, was defined as bleeding that generates radiological signs of intracranial hypertension either by volume or by mass effect on the routine CT scan 24 hours after surgery. Other tumor features and hemostasis variables were analyzed. Chi-squared and Fisher’s exact test were used in the inferential analysis for qualitative variables and Wilcoxon and T-Test for quantitative ones. P - value < 0.05 was considered significant for a confidence interval of 95%.

Results: A total of 109 patients operated on brain tumor surgery were finally included, 69 male (63,30%) and 40 female (36,70%), with a mean age of 54,60 ± 14,75 years. ICH was confirmed in 39 patients (35,78%). Their average of DDimer was A-1.526,70 ng/dl, B-1.061,88 ng/dl, and C-1.330,91 ng/dl (A p0.039, B p0,223 C p0.042, W-Wilcoxon test). The male group was also associated with ICH (p0,030 X2 test). Of those 39 patients with ICH, 30 in sample A (76,9%), 20 in sample B (51,28%) and 35 in sample C (89,74%) had a D-dimer > 500 ng/dl (p0,092, p1, p0,761 X2 test) and the relative risk of developing a postoperative hematoma in this patients was increased 0,36-fold presurgery, 0,25-fold postsurgery and 0,40-fold 24 hours after surgery. D-dimer variation, had no statistical significance (p0,118, p0,195, p0,756 T-test). Platelets and prothrombin activity were associated with D-dimer levels only in sample A (p 0,02 and p 0,20, W Wilson).

Conclusion: High levels of perioperative D-dimer could be considered a risk marker of ICH after brain tumor surgery. However, more studies would be worthwhile to confirm this association and develop primary prevention strategies for stroke.

Cancer incidence is increasing globally, being a leading cause of death worldwide [1-3]. Though brain tumors are uncommon, they cause morbidity and mortality disproportionate to their incidence [4,5]. Despite individualized management and optimal surgical measures, a removal of a brain tumor carries a higher risk of intracerebral hemorrhage (ICH) [6,7]. Multifactorial and sometimes unexplained, it is likely the most feared complication leading to poor functional prognosis, even risk of death [8,9].

Functional integrity of the hemostatic system and normal standard coagulation tests are both required for safe neurosurgical procedures, but other specific acquired hemostatic disorders, not routinely measured, could be developed during cancer surgery and increase or predict bleeding risk [10-12].

D-dimer, a fibrinogen compound with high molecular weight, formed during activation of the coagulation system, derived from the degradation of crosslinked fibrinogen when the dissolution of a fibrin clot, at the end of the coagulation cascade. Its activity is a global reflection of clot formation and lysis. It can’t be generated in vitro conditions after blood collection so, that formation is considered a reflection of in vivo hemostatic activity. So, it is appeared to be one of the most valuable parameters in thrombosis research [13,14].

Until a few years ago, plasma D-dimer variation was explained by prothrombotic and inflammatory tumoral state, insufficient control of an antiinflammatory response, multifactorial coagulopathy, surgery, or biological conditions. In spite of that, plasma measurement of D-dimer has become essential in clinical to exclude deep vein thrombosis, pulmonary embolism and disseminated intravascular coagulation. It is considered a biomarker of worse-outcome in cardiovascular disease, with a convincing evidence of association with ischemic stroke, but conflicting and potentially more complex with ICH, until now [15-18].

Poor neurological outcome and high disability scores after ICH have lately increased the interest to determine new biomarkers of bleeding. The recent literature suggested that D-dimers can be used to evaluate and predict clinical prognosis in neurosurgical patients, including after subarachnoid hemorrhage, ICH, ischemic stroke, trauma, dural arteriovenous fistula and intracerebral neoplasms [19-23].

Increasing incidence and morbi-mortality of brain tumors conducted this study to evaluate perioperative plasma D-dimer as risk biomarker of bleeding after brain tumor surgery.

It should be noted during the COVID-19 pandemic, early and effective predictors of clinical outcomes were urgent needed for risk stratification. It has been reported COVID-19 was associated with hemostatic abnormalities and elevated D-dimer levels were observed in non-survivors. It was considered, with a nonwell established optimal cut-off, the earliest and most helpful biomarker to predict poorer outcomes and improve management. Thanks to the pandemic, the relevance of D-dimer was considered again [24-27].

A prospective, observational, 18-month study (July 2013-December 2014) was conducted in the Neurointensive Care Unit (N-ICU) at Miguel Servet University Hospital, a single third-level center in Spain. The study included all consecutive adults operated on elective brain tumor surgery by trained and experienced neurosurgeons with postoperative stay in the N-ICU. Dead people in the operating room, incomplete coagulation test (by lost or mistake) or nontumor tissue were exclusion criteria.

Two blood samples were drawn from a jugular central venous catheter placed prior to surgery (A-presurgery or baseline, B-postsurgery and C-24 hours after surgery). The cut-off value of D-dimer was < 500 mg/dl. D-Dimer was immediately measured with two autoanalyzers ACL-TOP 500 y 700 CTS by latex particle immunoassay. Competence and quality management of medical laboratory was accredited by ISO 15189: 2012 certification. Patients did not receive any prophylaxis or hemostatic therapy.

ICH, as a primary outcome, was defined as bleeding that generates radiological signs of intracranial hypertension (IH) either by volume or by mass effect on the routine head computerized tomography (CT) scan 24 hours after surgery. All CT scans were assessed by a comitte of neuroradiologists and neurosurgeons. Other filiation data were collected (age, gender, previous coagulopathy, origin and tumor tissue, routine hemostasis and hemogram parameters). Perioperative management of antiplatelet and antiacoagulant agents was properly considered.

Categorical variables were presented as frequencies and percentages. The association between qualitative variables was determined by Pearson Chisquared test (X2) or Fisher’s exact test. Wilconxon-test and T-Test were considered to stablish correlation between quantitative variables. P - value < 0.05 was significant for confidence interval of 95%.

Data collection worksheets were stored and analyzed by SPSS® Stadistic Software 21.0.0. Each participant was assigned a registration number to to data anonymization. Ethical approval for this study was obtained from Ethics Committee of Clinical Investigation in Aragon (CEICA, nº CP14/2013).

A total of 120 patients were operated on neurosurgery during 18 months. But finally 12 of them were excluded, 10 due to incomplete blood sample and two due to absence of tumor tissue in the histophatological analysis. From 109 patients, 69 were male (63,30%) and 40 female (36,70%) with a mean age of 54,60 ± 14,75 years; 34 patients (31,2%) were < 50 years old.

Primary tumor resection (68,80%) was more common than recurrent tumor (21,10%) and metastases (10,09%). There were different histological types of brain tumor, being high-grade glioma the most prevalent (39,44%) followed by meningioma (27,52%). The least common was mesenchymal (4,58%). Volume were < 30 ml in most of them (64%) and subtotal removal (≥ 90% of volumen) was possible in more than 85%. Most patients (71,5%) did not have postoperative neurological complications: focal neurologic deficit 24,77% was the most prevalent, followed by headache (5,5%). Only eleven patients (10%) suffered from critical care complication, 8 of them sepsis. According to hemostasis and bleeding disorders, one patient had unexplained preoperative anemia 8,9 g/dl and another one a previous inherited condition (glucose-6phosphate dehydrogenase deficiency G6PDD).

Fifteen units of blood products were transfused, 12 of 14 were intraoperative red blood cells (RBC) and also, intraoperative, 1 pooled platelets (PP). 5 patients needed TXA and 1 prothrombin complex (PC). Noone needed neither frozen plasma (FP) nor FVIIa.

The average length of stay in ICU was 3,34 ± 2,77 days. All patients, except two who died due to massive ICH, were discharged from ICU to neurosurgery hospital floor (Table 1).

Table 1: Clinical and tumor data and ICH.
  ICH No ICH p value
Age < 50 y.o 12 22 0,73
> 50 y.o 27 48
Gender Male 30 39 0,03
Female 9 31
Tumor origin Primary 25 50 0,25
Recurrent or
14 20
Histopathology Meningioma 9 21 0,22
Glioma 21 32
Others 1 14
Metastasis 8 3
Tumor volume NMR < 29 ml 23 47 0,06
≥ 30 ml 26 23
% Tumor removal ≥ 90% 31 8 0,47
< 89% 62 8
Postoperative complications Seizures 0 1 > 0,1
Hydrocephalus 0 1
Headache 2 4
Ischemia 2 2
Neurologic Deficit 13 14
Sepsis 5 3
Transfusion Red cells 6 8 > 0,1
Platelets 1 0
Frozen plasma 0 0
FVII 0 0
Protrombin complex 1 0
Tranexamic acid 4 1
ICU stay  (mean days) 3,34 ± 2,77 1,88 ± 1,31   < 0,01
Death Death 2 0 0,06
No death 37 70

Most of patients suffered from minimal disorders in routine hemostasis and hemogram parameters (hemoglobin (Hb), hematocrit (Ht) platelets (P), international normalized ratio (INR), activated partial thromboplastin time (APTT), Prothrombin Activity (PA) and fibrinogen (Fb)) but within normal ranges (Tables 2-4). It should be highlighted that antiplatelet and anticoagulant therapy were both adequately stopped. Despite normal routine and specific baseline hemostasis and coagulation, male with G6PDD suffered from ICH and needed 2 intraoperative RBC.

Table 2: Routine hemogram and hemosthasis. A- Sample.
  Minimum Maximum Mean SD
Hb 8,90 17,40 13,34 1,66
Ht 26,80 53,50 39,53 4,69
P 90000 310000 180729,73 52838,67
INR 0,40 1,16 0,97 0,098
APTT 17,40 39,70 26,49 4,14
PA 32 162 102,06 16,70
Fb 0,90 8 3,04 1,27
Table 3: Routine hemogram and hemosthasis. B-Sample.
  Minimum Maximum Mean SD
Hb 8,10 16,40 12,50 1,45
Ht 19,20 47,40 37,30 4,69
P 59000 196000 184784,95 192237,39
INR 0,84 9,20 1,08 0,82
APTT 11,00 86,6 26,85 7,91
PA 42,00 136,00 101,58 13,48
Fb 1,10 8,80 3,19 1,32
 Table 4: Routine hemogram and hemosthasis. C- Sample.
  Minimum Maximum Mean SD
Hb 7,90 15,85 12,25 1,45
Ht 24,20 47,90 36,90 4,31
P 70000 327000 165310,00 51574, 34
INR 0,77 1,24 1,00 0,08
APTT 21,10 37,70 27,35 2,93
PA 72 158,00 100,48 13,35
Fb 1,70 7,20 4,24 1,11

ICH was finally confirmed in 39 patients (35,78%). The average of D-dimer in those patients was A-1.526,70 ng/dl, B-1.061,88 ng/dl and C-1.330,91 ng/dl. HDD-dimer levels were lower in patients without ICH A-543,97 ng/dl, B-572,02 ng/dl and C-965,23 ng. Maximum value of D-dimer in sample A was 15.053 ng/dl and minimum 39 ng/dl, 5.043 ng/dl and 46 ng/dl in B and 5.494 ng/dl and 36 ng/dl in C respectively (Table 5).

Table 5: D-dimer levels in ICH/no ICH group.
  N Mean SD SEM
  Dd-A ICH 39 1526,70 3149,980 671,578
no ICH 70 543,97 762,344 130,741
  Dd-B ICH 39 1061,88 1217,571 238,785
no ICH 70 572,02 595,984 83,454
  Dd-C ICH 39 1330,91 1176,957 2014,882
no ICH 70 965,23 1199,463 164,759

Inferential analysis determined that none of the clinical and tumor data analyzed were statistically associated with ICH, except male group (p0,030 X2 test) and ICU stay (< 0,01 W Wilconxon) (Table 1).

Increased levels of D-dimer A and C were associated with ICH (A p0.039, B p0,223 and C p0.042 W-Wilconxon test) (Table 6), but not in patients without ICH. No differences also in D-dimer variation (A-B p0,118, A-C p0,195, B-C p0,756 T-test) (Table 7).

Table 6: D-dimer and ICH.
W Wilcoxon Z Bil. A Sig
Dd-A 846,000 -2,064 0,039
Dd-B 2365,000 -1,218 0,223
Dd -C 2076,000 -2,038 0,042
 Table 7: D-dimer variation in ICH/no ICH group.
  N Mean DS SEM T-test Bil. Sig
A-B Dd ICH 39 969,4667 3023,51834 780,66908 0,118
no ICH 70 -65,0000 1135,88224 218,60064
A-C Dd ICH 39 440,4750 2904,29784 649,42074 0,195
no ICH 70 -344,3929 1065,71709 201,40160
B-C Dd ICH 39 -352,6000 981,20275 144,91832 0,756
no ICH 70 -429,1875 1004,02356 196,24055

Postoperative D-dimer levels were extremely elevated in the two patients who suffered from ICH associated with ischemic stroke and also in the three blood samples in those who died. -It should be noted that among patients with ICH, 30 of them (76,9%), in sample A, 20 (51,28%) in sample B and 35 (89,74%) in sample C had D-dimer levels > 500 ng/dl, compared with D-dimer levels < 500 ng/dl (p0,092, p1, p0,761 X2 test).

The relative risk of developing a postoperative hematoma was increased 0,36-fold presurgery, 0,25-fold postsurgery and 0,40-fold 24 hours after surgery in patients with D-dimer > 500 ng/dl, respectively.

Regression analysis showed plasma D-dimer levels were statistically associated only with baseline P and PA (p0,02, p0,20, Pearson correlation) (Tables 8-10). Significant association between standard coagulation and ICH was demonstrated only with baseline APTT and postoperative P (p0,020, p0,033 Wilconxon test) (Tables 11-13).

 Table 8: Standard coagulation and D-dimer –A.
Dd 1,000 -,077 -,059 ,413 -,172 -,248 ,307 -,222
Hb -,077 1,000 ,863 -,172 -,156 -,348 -,022 -,025
Ht -,059 ,863 1,000 -,077 -,116 -,365 ,013 ,006
P ,413 -,172 -,077 1,000 -,029 -,188 ,070 -,080
INR -,172 -,156 -,116 -,029 1,000 ,261 -,693 ,137
APTT -,248 -,348 -,365 -,188 ,261 1,000 -,266 ,173
PA ,307 -,022 ,013 ,070 -,693 -,266 1,000 -,033
Fb -,222 -,025 ,006 -,080 ,137 ,173 -,033 1,000
      Sig Dd ,308 ,349 ,002 ,129 ,051 ,020 ,071
Hb ,308 ,000 ,130 ,154 ,010 ,442 ,436
Ht ,349 ,000 ,307 ,223 ,007 ,467 ,485
P ,002 ,130 ,307 ,426 ,109 ,324 ,300
INR ,129 ,154 ,223 ,426 ,042 ,000 ,184
APTT ,051 ,010 ,007 ,109 ,042 ,039 ,128
PA ,020 ,442 ,467 ,324 ,000 ,039 ,415
Fb ,071 ,436 ,485 ,300 ,184 ,128 ,415
 Table 9: Standard coagulation and D-dimer –B.
        Pearson Correlation Dd 1,000 ,121 -,096 -,071 -,076 -,092 ,027 -,066
Hb -,121 1,00 ,489 ,019 ,164 -,014 -,116 ,091
Ht -,096 ,489 1,000 ,025 ,214 -,032 ,174 ,116
P -,071 ,019 ,025 1,000 -,010 ,015 ,058 ,004
INR -,076 ,164 ,214 -,010 1,000 -,098 ,070 -,021
APTT -,092 ,014 -,032 ,015 -,098 1,000 -,192 ,125
PA ,027 ,116 ,174 ,058 ,070 -,192 1,000 -,370
Fb -,066 ,091 ,116 ,004 -,021 ,125 -,370 1,000
      Sig. Dd ,151 ,206 ,273 ,259 ,215 ,410 ,288
Hb ,151 ,000 ,434 ,080 ,453 ,161 ,218
Ht ,206 ,000 ,416 ,033 ,391 ,068 ,161
P ,273 ,434 ,416 ,468 ,449 ,311 ,487
INR ,259 ,080 ,033 ,468 ,202 ,274 ,431
APTT ,215 ,453 ,391 ,449 ,202 ,050 ,142
PA ,410 ,161 ,068 ,311 ,274 ,050 ,001
Fb ,288 ,218 ,161 ,487 ,431 ,142 ,001
  1. Table 10: Standard coagulation and D-dimer –C.
Dd 1,000 -,162 -,072 -,094 ,098 -,073 -,107 ,105
Hb -,162 1,000 ,191 -,172 -,037 -,150 -,001 -,144
Ht -,072 ,191 1,000 -,159 -,143 -,052 ,138 ,000
P -,094 -,172 -,159 1,000 ,001 ,088 -,040 ,137
INR ,098 -,037 -,143 ,001 1,000 ,093 -,921 ,170
TTPA -,073 -,150 -,052 ,088 ,093 1,000 -,169 -,024
PA -,107 -,001 ,138 -,040 -,921 -,169 1,000 -,121
Fb ,105 -,144 ,000 ,137 ,170 -,024 -,121 1,000
      Sig. Dd ,074 ,262 ,201 ,191 ,257 ,170 ,175
Hb ,074 ,044 ,062 ,370 ,091 ,497 ,100
Ht ,262 ,044 ,078 ,101 ,321 ,110 ,499
P ,201 ,062 ,078 ,498 ,217 ,362 ,111
INR ,191 ,370 ,101 ,498 ,206 ,000 ,064
APTT ,257 ,091 ,321 ,217 ,206 ,066 ,414
PA ,170 ,497 ,110 ,362 ,000 ,066 ,141
Fb ,175 ,100 ,499 ,111 ,064 ,414 ,141
 Table 11: Standard coagulation –A and ICH.
  W de Wilcoxon Z Sig. asintót. (bilateral)
Hb 1760,500 -0,022 0,982
Hto 937,000 -0,564 0,573
Plaq 897,500 -1,292 0,197
INR 2132,000 -0,892 0,372
TTPA 1015,500 -2,318 0,020
AP 1160,000 -0,948 0,343
Fb 1168,500 -0,602 0,547
 Table 12: Standard coagulation – B and ICH.
W de Wilcoxon Z Sig. asintót. (bilateral)  
Hb 1421,500 -1,040 0,298
Hto 1416,500 -0,961 0,337
Plaq 1285,500 -2,132 0,033
INR 2975,000 -1,849 0,064
TTPA 1798,500 -0,140 0,889
AP 1619,500 -1,426 0,154
Fb 1660,000 -,659 0,510
Table 13: Standard coagulation – C and ICH.
W de Wilcoxon Z Sig. asintót. (bilateral)  
Hb 1577,000 -1,731 0,083
Hto 1528,500 -1,868 0,062
Plaq 1608,000 -1,508 0,132
INR 3313,000 -0,603 0,547
TTPA 1813,000 -0,287 0,774
AP 1742,000 -0,667 0,505
Fb 1721,500 -0,929 0,353

Poor neurological outcomes after ICH increased the interest in new biomarkers which could identify the risk of life-threatening complications and reliable prognostic criteria. Sequencial D-dimer levels have been traditionally determined to detect thromboembolism, structural disorder in traumatic brain injury, as a worse-outcome marker in cardiovascular disease and, despite beeing uncommon in neurosurgery field, also in prognosis after stroke, but mainly ischemic [28-31].

Juvela, et al. [32] analyzed D-dimer after aneurysmal ICH, with worse long-term results and more advanced stages if elevated, being probably useful as a risk marker of poor outcome. Delgado, et al. [33] predicted early neurologic deterioration and poor outcome after ICH with increased Ddimer levels in 98 consecutive acute ICH. Chiu, et al. [34] confirmed higher D-dimer level after spontaneuous ICH was associated with 30 day mortality and Castelnouvo [35] provided clear evidence in 832 patients that elevated levels of D-dimer were potential risk factor for both ischaemic and haemorrhagic stroke, similar findings to Zakai, et al. [20]. The largest meta-analysis, 13 studies including 891 ICH patients, conducted by Zhike Zhou, et al. [36] revealed that high level of D-dimer was associated with risk of ICH, so it was suggested to be a potential biomarker of bleeding in ICH.

Qi Zhou, et al. [21] confirmed recently in a retrospective design with 1.332 patients the elevation of D-dimer is an independent risk factor for poor functional prognosis and mortality in spontaneous ICH.

It is clear D-dimer’s role in coagulation and fibrinolytic systems is attractive, but the pathophysiologic mechanism on ICH has not been fully elucidated yet [21] and more studies focusing on hemorrhagic stroke would be needed to clear out the mechanism for this association, multifactorial probably: unclear hemostatic disorder, biological and surgical conditions, influence of transfusion- and finally heritability of a prethrombotic state.

Obviously, it is very difficult to discard the influence of all those factors on the results but, despite several limitations, this is the first prospective study in the literature to evaluate how perioperative D-dimer behaves in the presence of ICH and with the rest of the hemostatic parameters in order to consider it as a risk marker of unexplained bleeding.

Baseline and 24-hour after aggression samples were statistically associated with ICH, so high D-dimer could be considered as risk marker of bleeding and poor prognosis in the perioperative of brain tumor. Regression analysis only confirmed significant association with baseline P and PA, probably explained by hipercoaguability and inflammation. A larger sample would be necessary to be replaced.

In regard to standard parameters, several patients suffered from a minimal disorder during perioperative period, however statistical association with ICH only could be demonstrated with baseline APTT and postoperative P. This association seems to be coherent (by consumption coagulopathy during surgical agression in that tumoral state) but too specific without data to compare in the literature, so these results can not consider the standard parameters as risk markers.

This study is based on a small sample size of a single-center and there is no data available to compare with other brain tumor patients, so findings should be interpreted with caution. There is also no literature for gender and ICH. An increased prevalence of cardiovascular disease and spontaneous ICH is described in males so, it could explain our association [38-40]. But a larger sample size would be necessary to compare this and the other features after ICH. Obviously, several comorbidities, biological conditions, bleedings disorders, drugs, skills and surgical factors could influence bleeding. Although it is very difficult to control all these interfering factors, heterogeneity was minimal and epidemiologic and tumor features were similar to general population [1-6,37], perioperative management of antiplatelet and antiacoagulant agents was adequately considered, preoperative samples were carefully analized and neurosurgeons were experts on aplying the latest knowledge and minimally invasive neurosurgical techniques in brain tumors.

With regard to the main variable, the lack of established criteria in the literature lead to measure ICH objectively by a committe of neuroradiologists and neurosurgeons, avoiding evacuation criteria very controversial between studies. Other types of intracraneal hemorrhage (epidural, subdural and subarachnoid) and ischemic stroke were also evaluated in the CT scan. Fortunately, no more types of hemorrhage were diagnosed. High levels of postoperative D-dimer found in two patients with ischemic stroke and ICH were not considered for the analysis, however this result would support previous studies to consider high Ddimer as a potential risk marker for both ischaemic and haemorrhagic stroke with poor functional prognosis.

G6PD deficiency, considered latent and more severe in males, would manifest as hemolytic anemia. Despite normal preoperative hemostasis and coagulation, surgical aggression and/or some drugs could bring out this latent deficiency and lead to ICH. However, guidelines do not recommend prophylactic transfusion before major surgery. The association analysis was not considered with an only case [41,42].

All these findings would confirm that perioperative D-dimer levels could be a risk marker of ICH with a high impact on future research to screen patients at risk of stroke. More studies would be worthwhile to confirm this association and develope primary prevention strategies.

High levels of perioperative D-dimer could be considered a risk marker of ICH after brain tumor surgery. However, more studies would be worthwhile to confirm this association and develope primary prevention strategies for stroke.


Ethics approval and consent to participate: Written informed consent was required for all participants. Comité de Ética de Investigación de la Comunidad de Aragón (CEICA) approved the study (NºCP14/2013).

Availability of data and materials: All data generated or analyzed were included in this published article.

Authors contributions

Author’s contributions this study are:

EVJ: main author, design, methodology and writting

ANP: coordination and design

BVS: coordination and design

JCP: collection and analysis of neurosurgery data

NFM: blood sample analysis

LSG: visualization, writing-review, expert in brain injury

SRR: visualization, writing-review

NRC: visualization, writing-review

GJJ: visualization, writing-review

MQD: visualization, writing-review and editing, expert in hemotherapy

MDVG: design, methodology, visualization, writing-review

DFE: visualization, writing-review

CRL: statistical analysis

JCL: visualization, writing-review and editing.

  1. International Agency for Research on Cancer (IARC). Global Cancer Observatory 2020
  2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313. PMID: 30207593.
  3. You W, Henneberg M. Cancer incidence increasing globally: The role of relaxed natural selection. Evol Appl. 2017 Aug 24;11(2):140-152. doi: 10.1111/eva.12523. PMID: 29387151; PMCID: PMC5775494.
  4. National Cancer Institute. Cancer statistics. 2020
  5. Leece R, Xu J, Ostrom QT, Chen Y, Kruchko C, Barnholtz-Sloan JS. Global incidence of malignant brain and other central nervous system tumors by histology, 2003-2007. Neuro Oncol. 2017 Oct 19;19(11):1553-1564. doi: 10.1093/neuonc/nox091. PMID: 28482030; PMCID: PMC5737839.
  6. Brain tumours (primary) and brain metastases in adults. NICE guideline. NG 99. July 2018.
  7. Hemphill JC 3rd, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, Fung GL, Goldstein JN, Macdonald RL, Mitchell PH, Scott PA, Selim MH, Woo D; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015 Jul;46(7):2032-60. doi: 10.1161/STR.0000000000000069. Epub 2015 May 28. PMID: 26022637.
  8. Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26;133(4):e38-360. doi: 10.1161/CIR.0000000000000350. Epub 2015 Dec 16. Erratum in: Circulation. 2016 Apr 12;133(15):e599. PMID: 26673558.
  9. Steiner T, Al-Shahi Salman R, Beer R, Christensen H, Cordonnier C, Csiba L, Forsting M, Harnof S, Klijn CJ, Krieger D, Mendelow AD, Molina C, Montaner J, Overgaard K, Petersson J, Roine RO, Schmutzhard E, Schwerdtfeger K, Stapf C, Tatlisumak T, Thomas BM, Toni D, Unterberg A, Wagner M; European Stroke Organisation. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke. 2014 Oct;9(7):840-55. doi: 10.1111/ijs.12309. Epub 2014 Aug 24. PMID: 25156220.
  10. Lord AS, Gilmore E, Choi HA, Mayer SA; VISTA-ICH Collaboration. Time course and predictors of neurological deterioration after intracerebral hemorrhage. Stroke. 2015 Mar;46(3):647-52. doi: 10.1161/STROKEAHA.114.007704. Epub 2015 Feb 5. PMID: 25657190; PMCID: PMC4739782.                                                                                                                                                             
  11. Gulati D, Dua D, Torbey MT. Hemostasis in Intracranial Hemorrhage. Front Neurol. 2017 Mar 15;8:80. doi: 10.3389/fneur.2017.00080. PMID: 28360881; PMCID: PMC5351795.                                                                 
  12. Fujii Y, Takeuchi S, Harada A, Abe H, Sasaki O, Tanaka R. Hemostatic activation in spontaneous intracerebral hemorrhage. Stroke. 2001 Apr;32(4):883-90. doi: 10.1161/01.str.32.4.883. PMID: 11283387.
  13. Goldenberg NA, Jenkins S, Jack J, Armstrong-Wells J, Fenton LZ, Stence NV, Oleszek J, Boada R, Wilkening GN, Wilkinson C, Soep JB, Miyamoto SD, Bajaj L, Mourani PM, Manco-Johnson MJ, Bernard TJ. Arteriopathy, D-dimer, and risk of poor neurologic outcome in childhood-onset arterial ischemic stroke. J Pediatr. 2013 May;162(5):1041-6.e1. doi: 10.1016/j.jpeds.2012.11.035. Epub 2012 Dec 20. PMID: 23260102; PMCID: PMC4115645.
  14. Wang J, Ning R, Wang Y. Plasma D-dimer Level, the Promising Prognostic Biomarker for the Acute Cerebral Infarction Patients. J Stroke Cerebrovasc Dis. 2016 Aug;25(8):2011-5. doi: 10.1016/j.jstrokecerebrovasdis.2015.12.031. Epub 2016 May 24. PMID: 27234921.
  15. Haapaniemi E, Tatlisumak T. Is D-dimer helpful in evaluating stroke patients? A systematic review. Acta Neurol Scand. 2009 Mar;119(3):141-50. doi: 10.1111/j.1600-0404.2008.01081.x. Epub 2008 Aug 14. PMID: 18705677.
  16. Zi WJ, Shuai J. Plasma D-dimer levels are associated with stroke subtypes and infarction volume in patients with acute ischemic stroke. PLoS One. 2014 Jan 20;9(1):e86465. doi: 10.1371/journal.pone.0086465. Retraction in: PLoS One. 2022 Mar 30;17(3):e0266428. PMID: 24466108; PMCID: PMC3896474.
  17. Barber M, Langhorne P, Rumley A, Lowe GD, Stott DJ. Hemostatic function and progressing ischemic stroke: D-dimer predicts early clinical progression. Stroke. 2004 Jun;35(6):1421-5. doi: 10.1161/01.STR.0000126890.63512.41. Epub 2004 Apr 8. PMID: 15073383.
  18. Folsom AR, Gottesman RF, Appiah D, Shahar E, Mosley TH. Plasma d-Dimer and Incident Ischemic Stroke and Coronary Heart Disease: The Atherosclerosis Risk in Communities Study. Stroke. 2016 Jan;47(1):18-23. doi: 10.1161/STROKEAHA.115.011035. Epub 2015 Nov 10. PMID: 26556822; PMCID: PMC4696899.
  19. Zhang J, Song Y, Shan B, He M, Ren Q, Zeng Y, Liu Z, Liu H, Xu J. Elevated level of D-dimer increases the risk of stroke. Oncotarget. 2017 Dec 18;9(2):2208-2219. doi: 10.18632/oncotarget.23367. PMID: 29416765; PMCID: PMC5788633.
  20. Zakai NA, Olson NC, Judd SE, Kleindorfer DO, Kissela BM, Howard G, Cushman M. Haemostasis biomarkers and risk of intracerebral haemorrhage in the REasons for Geographic and Racial Differences in Stroke Study. Thromb Haemost. 2017 Aug 30;117(9):1808-1815. doi: 10.1160/TH17-03-0189. Epub 2017 Jul 6. PMID: 28692106; PMCID: PMC6309529.
  21. Zhou Q, Zhang D, Chen X, Yang Z, Liu Z, Wei B, Jin M, Feng K, Guo C, Sun J, Chen S, Zhang R, Piao X, Gareev I, Sun Z, Wang X, Li L, Zhao S, Yang G. Plasma D-dimer predicts poor outcome and mortality after spontaneous intracerebral hemorrhage. Brain Behav. 2021 Jan;11(1):462-468. doi: 10.1002/brb3.1946. Epub 2020 Nov 11. PMID: 33179455; PMCID: PMC7821563.
  22. Chen X, Shi S, Hu L. High Levels of D-Dimer are Associated with Poor Hospitalization Outcome of Spontaneous Intraparenchymal Haemorrhage. Neuropsychiatr Dis Treat. 2022 May 30;18:1079-1086. doi: 10.2147/NDT.S362331. PMID: 35669230; PMCID: PMC9166298.
  23. Karsy M, Kim R, Azab M, Harper J, Guan J, Eli I, Couldwell W. Higher Admission D-Dimer Values Are Associated With an Increased Risk of Nonroutine Discharge in Neurosurgery Patients. Cureus. 2020 Jul 27;12(7):e9425. doi: 10.7759/cureus.9425. PMID: 32864251; PMCID: PMC7450899.
  24. Esenwa C, Cheng NT, Luna J, Willey J, Boehme AK, Kirchoff-Torres K, Labovitz D, Liberman AL, Mabie P, Moncrieffe K, Soetanto A, Lendaris A, Seiden J, Goldman I, Altschul D, Holland R, Benton J, Dardick J, Fernandez-Torres J, Flomenbaum D, Lu J, Malaviya A, Patel N, Toma A, Lord A, Ishida K, Torres J, Snyder T, Frontera J, Yaghi S. Biomarkers of Coagulation and Inflammation in COVID-19-Associated Ischemic Stroke. Stroke. 2021 Nov;52(11):e706-e709. doi: 10.1161/STROKEAHA.121.035045. Epub 2021 Aug 25. PMID: 34428931; PMCID: PMC8547586.
  25. Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, Zhang Z. D-dimer levels on admission to predict in-hospital mortality in patients with COVID-19. J Thromb Haemost. 2020 Jun;18(6):1324-1329. doi: 10.1111/jth.14859. PMID: 32306492; PMCID: PMC7264730.
  26. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020 Apr;18(4):844-847. doi: 10.1111/jth.14768. Epub 2020 Mar 13. PMID: 32073213; PMCID: PMC7166509.
  27. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. PMID: 32171076; PMCID: PMC7270627.                                                                                                                 
  28. Gerlach R, Tölle F, Raabe A, Zimmermann M, Siegemund A, Seifert V. Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased factor XIII activity: implications of a prospective study. Stroke. 2002 Jun;33(6):1618-23. doi: 10.1161/01.str.0000017219.83330.ff. PMID: 12053001.                                                                           
  29. Aishima K, Yoshimoto Y. Screening strategy using sequential serum D-dimer assay for the detection and prevention of venous thromboembolism after elective brain tumor surgery. Br J Neurosurg. 2013 Jun;27(3):348-54. doi: 10.3109/02688697.2012.737958. Epub 2012 Nov 7. PMID: 23131147.
  30. Natsumeda M, Uzuka T, Watanabe J, Fukuda M, Akaiwa Y, Hanzawa K, Okada M, Oishi M, Fujii Y. High Incidence of Deep Vein Thrombosis in the Perioperative Period of Neurosurgical Patients. World Neurosurg. 2018 Apr;112:e103-e112. doi: 10.1016/j.wneu.2017.12.139. Epub 2017 Dec 30. PMID: 29294399.                                                                                                                                                
  31. Sugimoto K, Suehiro E, Shinoyama M, Sadahiro H, Haji K, Fujiyama Y, Kawano R, Nishioka M, Suzuki M. D-Dimer Elevation as a Blood Biomarker for Detection of Structural Disorder in Mild Traumatic Brain Injury. J Neurotrauma. 2017 Dec 1;34(23):3245-3248. doi: 10.1089/neu.2017.5240. Epub 2017 Oct 27. PMID: 28895444.                                                                                                                
  32. Juvela S, Siironen J. D-dimer as an independent predictor for poor outcome after aneurysmal subarachnoid hemorrhage. Stroke. 2006 Jun;37(6):1451-6. doi: 10.1161/01.STR.0000221710.55467.33. Epub 2006 May 11. PMID: 16690901.
  33. Delgado P, Alvarez-Sabín J, Abilleira S, Santamarina E, Purroy F, Arenillas JF, Molina CA, Fernández-Cadenas I, Rosell A, Montaner J. Plasma d-dimer predicts poor outcome after acute intracerebral hemorrhage. Neurology. 2006 Jul 11;67(1):94-8. doi: 10.1212/01.wnl.0000223349.97278.e0. PMID: 16832084.
  34. Chiu CC, Li YN, Lin LJ, Hsiao CT, Hsiao KY, Chen IC. Serum D-dimer as a predictor of mortality in patients with acute spontaneous intracerebral hemorrhage. J Clin Neurosci. 2012 Jun;19(6):810-3. doi: 10.1016/j.jocn.2011.08.032. Epub 2012 Feb 28. PMID: 22377638.
  35. Di Castelnuovo A, Agnoli C, de Curtis A, Giurdanella MC, Sieri S, Mattiello A, Matullo G, Panico S, Sacerdote C, Tumino R, Vineis P, de Gaetano G, Donati MB, Iacoviello L. Elevated levels of D-dimers increase the risk of ischaemic and haemorrhagic stroke. Findings from the EPICOR Study. Thromb Haemost. 2014 Nov;112(5):941-6. doi: 10.1160/TH14-04-0297. Epub 2014 Jul 17. PMID: 25030937.                                                                                                       
  36. Zhou Z, Liang Y, Zhang X, Xu J, Kang K, Qu H, Zhao C, Zhao M. Plasma D-Dimer Concentrations and Risk of Intracerebral Hemorrhage: A Systematic Review and Meta-Analysis. Front Neurol. 2018 Dec 20;9:1114. doi: 10.3389/fneur.2018.01114. PMID: 30619067; PMCID: PMC6306414.
  37. Ariesen MJ, Claus SP, Rinkel GJ, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke. 2003 Aug;34(8):2060-5. doi: 10.1161/01.STR.0000080678.09344.8D. Epub 2003 Jul 3. PMID: 12843354.
  38. Mancia G. Clinical practice guideline of the ESH/ESC for the management of arterial hypertension. Working Group for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology. 2013: 3.
  39. Gokhale S, Caplan LR, James ML. Sex differences in incidence, pathophysiology, and outcome of primary intracerebral hemorrhage. Stroke. 2015 Mar;46(3):886-92. doi: 10.1161/STROKEAHA.114.007682. Epub 2015 Feb 5. PMID: 25657181.                                                                                                        
  40. Gabriel R et al. Prevalence, distribution and geographical variability of the main cardiovascular risk factors in Spain. Pooled analysis of individual data from population-based epidemiological studies: the ERICE study. RevEspCardiol.2008:1030-40                                                                  
  41. Frank JE. Diagnosis and management of G6PD deficiency. Am Fam Physician. 2005 Oct 1;72(7):1277-82. PMID: 16225031.
  42. Glucose-6-Phosphate-Dehydrogenase deficiency. Hematology and Hemotherapy. 2012.